This disclosure presents embodiments of novel strains of Staphylococcus aureus that through genetic engineering produce type 5 capsular polysaccharide at greater levels than Staphylococcus aureus strain Reynolds.
1. A strain of Staphylococcus aureus comprising a constitutive promoter wherein said constitutive promoter is operably linked to a cap5 operon wherein said constitutive promoter is the cap1 promoter of Staphylococcus aureus strain M comprising SEQ ID NO 2.
2. A strain of Staphylococcus aureus comprising a constitutive promoter wherein said constitutive promoter is operably linked to a cap5 operon wherein said constitutive promoter is the cap1 promoter of Staphylococcus aureus strain M comprising SEQ ID NO 2, and wherein the cap1 promoter and cap5 operon comprise the deoxyribonucleic acid sequence SEQ ID NO: 6.
3. The strain of Staphylococcus aureus of claim 1 , wherein type 5 capsular polysaccharide production is five-fold greater than Staphylococcus aureus strain Reynolds.
4. The strain of Staphylococcus aureus of claim 1 , wherein type 5 capsular polysaccharide production is nine-fold greater than Staphylococcus aureus strain Reynolds.
5. The strain of Staphylococcus aureus of claim 1 , wherein type 5 capsular polysaccharide production is 11.5-fold greater than Staphylococcus aureus strain Reynolds.
6. An isolated deoxyribonucleic acid sequence comprising SEQ ID NO 5.
7. An isolated deoxyribonucleic acid sequence comprising SEQ ID NO 6.